- Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). La Rosée, P., Corbin, A.S., Stoffregen, E.P., Deininger, M.W., Druker, B.J. Cancer Res. (2002)









